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ABSTRACT
Objective: To compare real-world outcomes with newer (insulin glargine 300U/mL; Gla-300) versus
standard of care (SoC) basal insulins (BIs) in the REACH (insulin-naïve; NCT02967224) and REGAIN
(basal insulin-treated; NCT02967211) studies in participants with uncontrolled type 2 diabetes (T2DM)
in Europe and Brazil.
Methods: In these open-label, parallel-group, pragmatic studies, patients (HbA1c > 7.0%) were
randomized to Gla-300 or SoC BI for a 6-month treatment period (to demonstrate non-inferiority of
Gla-300 vs SoC BIs for HbA1c change [non-inferiority margin 0.3%]) and a 6-month extension period
(continuing with their assigned treatment). Insulin titration/other medication changes were at investi-
gator/patient discretion post-randomization.
Results: Overall, 703 patients were randomized to treatment in REACH (Gla-300, n¼ 352; SoC, n¼ 351)
and 609 (Gla-300, n¼ 305, SoC, n¼ 304) in REGAIN. The primary outcome, non-inferiority of Gla-300
versus SoC for HbA1c change from baseline to month 6, was met in REACH (least squares [LS] mean
difference 0.12% [95% CI –0.046 to 0.281]) but not REGAIN (LS mean difference 0.17% [0.015–0.329]);
no between-treatment difference in HbA1c change was shown after 12 months in either study. BI dose
increased minimally from baseline to 12 months in REACH (Gla-300, þ0.17U/kg; SoC, þ0.15U/kg) and
REGAIN (Gla-300, þ0.11U/kg; SoC, þ0.07U/kg). Hypoglycemia incidence was low and similar between
treatment arms in both studies.
Conclusions: In both REACH and REGAIN, no differences in glycemic control or hypoglycemia out-
comes with Gla-300 versus SoC BIs were seen over 12 months. However, the suboptimal insulin titra-
tion in REACH and REGAIN limits comparisons of outcomes between treatment arms and suggests
that more titration instruction/support may be required for patients to fully derive the benefits from
newer basal insulin formulations.
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Many people with type 2 diabetes (T2DM) who initially
achieve glycemic control with oral antihyperglycemic drugs
(OADs) eventually require basal insulin, either alone or in
combination with other agents1. Although a recent ADA/
EASD consensus report recommends that glucagon-like pep-
tide-1 receptor agonists (GLP-1 RAs) be used as the first
injectable therapy option2, basal insulins still play a key role
in the management of people with T2DM who are uncon-
trolled on OADs with or without GLP-1 RAs3. In clinical prac-
tice, basal insulin initiation is frequently delayed until
glycated hemoglobin (HbA1c) is >9% (>75mmol/mol)
4.
Newer second-generation basal insulin analogs such as
insulin glargine 300U/mL (Gla-300) were developed to
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optimize glycemic control while minimizing the risk of hypo-
glycemia. Gla-300 provides a more constant and prolonged
pharmacokinetic and pharmacodynamic profile than insulin
glargine 100U/mL (Gla-100, a standard of care [SoC] in basal
insulin treatment5), and equivalent glycemic control with
reduced risk of anytime (24 h) or nocturnal hypoglycemia, in
randomized controlled trials (RCTs) of people with T2DM6–9.
Furthermore, a lower risk of hypoglycemia with Gla-300 dur-
ing the initial weeks of treatment (the titration period) has
been consistently shown in regulatory RCTs versus Gla-100,
and has also been demonstrated versus insulin degludec6–10.
Consistent with RCTs, Gla-300 has shown comparable HbA1c
reduction with fewer hypoglycemic episodes versus first-
generation basal insulin analogs in retrospective, non-inter-
ventional real-world evidence (RWE) studies11,12.
Even after initiation, those using basal insulin frequently
experience poor glycemic control, which may be related to
insulin dose up-titration13, that is often suboptimal in real-world
practice4,14. Such therapeutic inertia (a phenomenon that
includes delayed therapy initiation, lack of dose adjustment
and delayed therapy intensification13), which probably contrib-
utes to the low level of HbA1c target achievement in routine
clinical practice4,15, may be related to perceived barriers such
as hypoglycemia and weight gain13,14,16–18. We hypothesized
that the use of newer basal insulin (such as Gla-300) in clinical
practice may allow people with T2DM to titrate appropriately
to achieve glycemic control with minimal hypoglycemia,
thereby overcoming therapeutic inertia. However, although
results from non-interventional real-world studies are interesting
and may better reflect clinical practice than regulatory RCTs,
comparisons between treatments in such studies may be con-
founded even if factors are fully controlled by appropriate stat-
istical methods such as propensity score matching.
Here we present the results of two studies that combine
real-world relevance with the advantages of randomization, a
methodology which, uniquely, is a perfect instrument to
address confounding. These studies aim to evaluate the real-
world effectiveness of newer basal insulin, Gla-300, compared
with other SoC basal insulins, in insulin-naïve (the REACH
CONTROL trial) and basal insulin-treated (the REGAIN
CONTROL trial) participants with uncontrolled T2DM. REACH
and REGAIN are the first randomized real-life studies (often
known as pragmatic studies as they aim to assess the out-
comes of treatment in routine clinical practice, rather than in
the controlled explanatory setting of a regulatory RCT19)
using basal insulin treatments in Europe and Brazil, and the
first such studies in the field of basal insulin therapy. The
studies were intended to allow for direct treatment compari-
sons in a real-life setting, and also provide an opportunity to
determine whether this pragmatic study design is a valid
approach to investigate the impact of novel therapies on
therapeutic inertia.
Materials and methods
Study design and participants
REACH CONTROL (NCT02967224) and REGAIN CONTROL
(NCT02967211) were multicenter, open-label, randomized,
active-controlled, 2-arm, parallel-group, comparative, pragmatic
real-world studies in patients with uncontrolled T2DM who
were either insulin-naïve but considered eligible for basal insu-
lin therapy (REACH; conducted in Brazil, France, Germany, Italy,
Romania, Spain, United Kingdom) or already on basal insulin
therapy (REGAIN; conducted in Brazil, Finland, France, Italy,
Romania, Spain, Switzerland, United Kingdom). Participants
underwent a 1-week screening period, followed by a 6-month
treatment period (for assessment of the primary outcome) and
a 6-month extension period (during which patients continued
within their assigned treatment arm) (Supplementary Figure 1),
to evaluate durability of clinical benefit, as well as patient-
reported outcomes (PROs) and healthcare resource utilization.
Patients attended four study visits during the 12-month ran-
domization period. Both trials were approved by local/national
institutional review boards/independent ethics committees, as
appropriate, and were performed in accordance with the
Declaration of Helsinki and the International Conference on
Harmonization guidelines for Good Clinical Practice. All partici-
pants provided written informed consent.
Participants were aged 18 years with uncontrolled T2DM
(HbA1c >7.0%) after 6 months of treatment with or
without GLP-1RA therapy and either (i) current OADs
(REACH) or (ii) basal insulin therapy with/without OADs
(REGAIN). Permitted OADs were metformin, sulfonylureas
(SU), thiazolidinediones, dipeptidyl peptidase 4 (DPP-4)
inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibi-
tors, glinides, a-glucosidase inhibitors. SoC basal insulin
therapy included Gla-100, insulin detemir, neutral protamine
Hagedorn (NPH) insulin or insulin degludec. Participants in
REGAIN were also required to have a fasting plasma glucose
(FPG) concentration of >130mg/dL (>7.2mmol/L) to justify
the need to intensify the current basal insulin treatment.
Exclusion criteria included the presence of any clinically sig-
nificant abnormality that would restrict successful participation
in the study, use of OADs not specified in the inclusion criteria,
use of GLP-1RA not approved for use with insulin, or use of
any drug in the context of a clinical trial within 3 months prior
to screening. Participants in REGAIN were also excluded if they
had received short-/rapid-acting insulin (e.g. human recombin-
ant insulin, insulin lispro, insulin aspart, insulin glulisine, inhaled
human insulin, pre-mix insulin, and biosimilars) during the
3 months prior to screening, other than for temporary use dur-
ing hospitalization. Additional exclusion criteria are listed in the
Supplementary Material.
Randomization and treatment
Randomization (1:1) either to Gla-300 or to any SoC basal
insulin (all commercially available long- or intermediate-act-
ing basal insulins, chosen at the investigator’s discretion
based on their clinical practice) was performed centrally by
an interactive response technology (IRT) system; the investi-
gator called the IRT system after the screening visit for allo-
cation of the patient number, and again on Day 1 when the
system randomized the patients to one of the treatment
arms. Randomization was stratified according to HbA1c cat-
egory (<9% or 9%) at screening, SU use at the time of
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randomization, and GLP-1RA use within 6 months prior to
randomization. Gla-300 was to be self-administered once-
daily at approximately the same time of day. SoC basal insu-
lins were to be administered once- or twice-daily according
to approved labeling and clinical practice. If needed, partici-
pants randomized to SoC basal insulin could switch to any
other SoC basal insulin, except Gla-300, during the treatment
period. Where available, participants were offered either a
specific, designated patient support program (PSP) (Gla-300
arm only) or a PSP as per the investigator’s usual practice
(any patient assigned to SoC), to help them achieve success-
ful insulin initiation and overall self-management, but this
was not compulsory. The PSP for Gla-300 (COACH) has been
described previously20,21, and includes tailored disease edu-
cation, product support, and encouragement for lifestyle
changes, but does not include specific titration support.
The approved insulin delivery devices for study drugs
were distinguishable; therefore, this was an open-label study.
However, HbA1c and FPG were analyzed in central laborato-
ries that were blinded to study drug received by the patient,
and the sponsor and investigators were blinded to the
results prior to database lock.
Dose and titration
The administered dose of Gla-300 or SoC basal insulin was at
the investigator’s discretion according to their standard prac-
tice and the patient’s characteristics and requirements, and
dependent on self-monitored plasma glucose data and
occurrence of hypoglycemia. The recommended starting
dose of Gla-300 was in line with the country-specific label,
taking into account glucose control and patterns of hypogly-
cemia in each patient. In brief, the starting dose of Gla-300
was to be 0.2 U/kg in REACH and the same dose as the pre-
viously used basal insulin (adapted as per the Gla-300 label
in those previously on a twice-daily regimen) in REGAIN. The
recommended target range for FPG was 80–130mg/dL
(4.4–7.2mmol/L), as per American Diabetes Association (ADA)
guidelines22. Insulin dose could be adjusted in order to
achieve this target or other local practice guidelines, and gly-
cemic targets could be adapted if it was deemed necessary
by the investigator according to individual participant con-
siderations. Importantly and in keeping with the real-world
nature of the study, no protocol-recommended titration algo-
rithm or oversight of titration outside of local clinical practice
was performed. It was recommended that Gla-300 dose
changes did not occur more frequently than every 3–4 days,
in line with the EU label23. Modification of concomitant anti-
hyperglycemic medication use (i.e. discontinuation or initi-
ation) was performed according to local clinical practice and
based on the investigator’s discretion.
Outcomes
The primary outcome was change in HbA1c from baseline to
month 6, to demonstrate the non-inferiority of Gla-300 versus
SoC basal insulin therapy. Secondary outcomes included the
proportion of participants reaching HbA1c targets (<6.5%,
<7.0%, <7.5% and <8.0%) at months 6 and 12, the percent-
age of participants whose HbA1c decreased by 1% (REACH)
or 0.5% (REGAIN) at months 6 and 12, change in FPG from
baseline to months 6 and 12 and the proportion of partici-
pants remaining on assigned basal insulin therapy during the
6- and 12-month randomized periods, with or without intensi-
fication (defined as addition of any OAD, GLP1-RA and/or
rapid-acting insulin medication, or an increase in dose of anti-
hyperglycemic medication already in use).
Safety outcomes included hypoglycemia episodes, includ-
ing incidence of nocturnal (00.00am–05.59am) and anytime
(24 h) hypoglycemic events, and documented symptomatic
or severe events. Hypoglycemia was classified according to
ADA criteria24, similar to the definition used in the pivotal
studies of Gla-3006,7. Documented symptomatic hypogly-
cemia was defined as an event with typical symptoms of
hypoglycemia accompanied by a PG concentration of
70mg/dL, (3.9mmol/L) (<54mg/dL [<3.0mmol/L] was
also analyzed). Severe hypoglycemia was defined as an event
requiring assistance from a third party to administer carbohy-
drate, glucagon or other resuscitative actions. Other safety
outcomes included adverse events (AEs) and serious adverse
events (SAEs), injection-site and hypersensitivity reactions,
vital signs and change in body weight from baseline to
months 6 and 12. Although not classified as a safety out-
come, basal insulin dose (U and U/kg) was also assessed.
Statistical methods
For REACH and REGAIN, a sample size of 340 and 290 patients,
respectively, per treatment group was determined in order to
provide 90% power to ensure that the upper confidence limit
of the 2-sided 95% confidence interval (CI) for the mean differ-
ence between Gla-300 and an SoC basal insulin did not exceed
0.3% (a non-inferiority margin recommended by the EMA25),
assuming a particular standard deviation (SD) (1.4% in REACH
and 1.3% in REGAIN) and that the true difference in HbA1c
between Gla-300 and a SoC basal insulin was 0.05%. The
power calculation was based on a 2-sample t-test for mean dif-
ference and was performed using the PROC POWER procedure
in SAS software version 9.3, SAS Institute Inc., Cary, NC, USA.
The primary analysis was conducted on all randomized
patients following the intent-to-treat (ITT) principle. Change in
HbA1c from baseline to month 6 was analyzed in the ITT
population using a mixed-effect model with repeated measures
(MMRM), with fixed categorical effects of treatment arm, visit,
treatment-by-visit interaction, multi-country organisation, ran-
domization strata of SU use (yes/no), randomization strata of
GLP-1 receptor agonist use (yes/no), as well as continuous
fixed covariates of baseline HbA1c and baseline HbA1c value-
by-visit interaction. The same model was used to analyze
HbA1c change to month 12, with the exception that one
additional level was added to the “visit” factor. For the
primary endpoint, a stepwise closed testing approach was
used to assess non-inferiority and superiority sequentially.
Non-inferiority (and superiority, if non-inferiority was shown) of
Gla-300 versus SoC basal insulin was demonstrated if the
upper bound of the 2-sided 95% CI for the between-treatment
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difference in mean change of HbA1c from baseline to month 6
was less than the predefined margin of 0.3% (or <0% for
superiority). The test for the primary outcome was performed
one-sided at level a¼ 0.025.
Secondary outcomes were analyzed descriptively in the ITT
population, where appropriate using either a mixed-effect
model with repeated measures or a logistic regression
approach, and no multiplicity adjustments were made. Safety
outcomes were assessed descriptively, with no statistical test-
ing, in the safety population, comprising all randomized partici-
pants who received 1 dose of study insulin. Participants were
analyzed according to treatment actually received, irrespective
of the randomized treatment arm. Odds ratios (ORs) and rate
ratios (RRs) for Gla-300 versus SoC basal insulins and their cor-
responding 95% CIs were provided, where applicable and esti-
mated using logistic and log binomial regression approaches,
respectively. The difference in the annualized rate of hypogly-
cemic events was evaluated using an over-dispersed Poisson
regression model. All analyses were undertaken using SAS soft-
ware version 9.3, SAS Institute Inc., Cary, NC, USA.
Results
Study participants
REACH was conducted between November 2015 and
October 2017 and REGAIN between December 2015 and
October 2017. Baseline characteristics for the overall study
populations of REACH (N¼ 703) and REGAIN (N¼ 609) are
presented in Table 1. The REGAIN population had longer
mean duration of diabetes, a lower proportion who were
receiving SUs or DPP-4 inhibitors at baseline and a higher
proportion receiving SGLT2 inhibitors at baseline compared
with the REACH population. Patient disposition throughout
both studies is shown in Supplementary Figure 2. Among
patients who did not complete the 12-month randomized
period in REACH (n¼ 30) and REGAIN (n¼ 28), there were 4
(Gla-300, n¼ 2; SoC basal insulin, n¼ 2) and 5 (Gla-300,
n¼ 3; SoC basal insulin, n¼ 2) deaths, respectively. The num-
ber of patients taking concomitant short-acting insulin,
mainly for intensification, during the 12-month randomized
periods were as follows: REACH, 21 patients (6.0%) in the
Gla-300 group and 31 patients (8.8%) in the SoC group;
REGAIN, 16 patients (5.2%) in the Gla-300 group and
14 patients (4.6%) in the SoC group. The most commonly
used SoC basal insulin over 12 months was Gla-100 in both
REACH (74%) and REGAIN (67%).
Outcomes
Change in HbA1c and insulin dose
In REACH, mean baseline HbA1c values were 8.99 (SD 1.40) %
(74.7 [15.3] mmol/mol) with Gla-300 and 9.08 (1.49) % (75.7
[16.3] mmol/mol) with SoC BIs. There was a similar change in














Age, years 61.4 ± 9.9 61.4 ± 10.0 61.4 ± 10.0 62.1 ± 10.1 62.0 ± 9.6 62.0 ± 9.9
Gender, male, n (%) 205 (58.2) 199 (56.7) 404 (57.5) 163 (53.4) 168 (55.3) 331 (54.4)
Weight, kg 87.7 ± 20.6 87.1 ± 18.5 87.4 ± 19.5 87.9 ± 19.9 88.2 ± 19.3 88.1 ± 19.6
Body mass index, kg/m2 31.2 ± 6.1 31.1 ± 5.8 31.1 ± 5.9 32.0 ± 6.1 32.0 ± 6.1 32.0 ± 6.1
Duration of diabetes, years 11.2 ± 7.4 10.9 ± 7.1 11.0 ± 7.2 13.8 ± 7.4 13.6 ± 7.8 13.7 ± 7.6
HbA1c
% 8.99 ± 1.40 9.08 ± 1.49 9.04 ± 1.45 8.58 ± 1.10 8.51 ± 1.18 8.55 ± 1.14
mmol/mol 74.8 ± 15.3 75.8 ± 16.3 75.3 ± 15.8 70.2 ± 12.0 69.6 ± 12.9 69.9 ± 12.5
FPG
mg/dL 210.1 ± 61.9 209.9 ± 70.5 210.0 ± 66.3 177.4 ± 56.8 181.4 ± 56.5 179.4 ± 56.6
mmol/L 11.7 ± 3.4 11.7 ± 3.9 11.7 ± 3.7 9.9 ± 3.2 10.1 ± 3.1 10.0 ± 3.1
Baseline anti-hyperglycemic medication, n (%)
Biguanides 308 (87.5) 320 (91.2) 628 (89.3) 268 (87.9) 264 (86.8) 532 (87.4)
Sulfonylureas 197 (56.0) 197 (56.1) 394 (56.0) 104 (34.1) 100 (32.9) 204 (33.5)
DPP-4 inhibitors 148 (42.0) 152 (43.3) 300 (42.7) 86 (28.2) 80 (26.3) 166 (27.3)
GLP-1 RAs 56 (15.9) 57 (16.2) 113 (16.1) 59 (19.3) 59 (19.4) 118 (19.4)
SGLT2 inhibitors 26 (7.4) 32 (9.1) 58 (8.3) 43 (14.1) 34 (11.2) 77 (12.6)
Glinides 26 (7.4) 20 (5.7) 46 (6.5) 30 (9.8) 18 (5.9) 48 (7.9)
Thiazolidinediones 18 (5.1) 6 (1.7) 24 (3.4) 5 (1.6) 6 (2.0) 11 (1.8)
Alpha-glucosidase inhibitors 8 (2.3) 15 (4.3) 23 (3.3) 1 (0.3) 7 (2.3) 8 (1.3)
None 1 (0.3) 0 (0) 1 (0.1) 4 (1.3) 5 (1.6) 9 (1.5)
Diabetes complications, n (%)
Neuropathy 74 (21.0) 87 (24.8) 161 (22.9) 78 (25.6) 75 (24.7) 153 (25.1)
Nephropathy 62 (17.6) 53 (15.1) 115 (16.4) 67 (22.0) 58 (19.1) 125 (20.5)
Retinopathy 44 (12.5) 32 (9.1) 76 (10.8) 69 (22.6) 73 (24.0) 142 (23.3)
Prescribed basal insulin, n (%)†
Glargine 300 U/mL 350 (100) 0 (0) n/a 304 (100) 0 (0) n/a
Glargine 100 U/mL n/a 259 (74.0) n/a n/a 204 (67.1) n/a
Detemir n/a 35 (10.0) n/a n/a 29 (9.5) n/a
Degludec n/a 18 (5.1) n/a n/a 28 (9.2) n/a
NPH n/a 38 (10.9) n/a n/a 43 (14.1) n/a
Information about diabetes complications was obtained from patient records/history at the screening visit, using pre-defined terms in the case report form.
†Data regarding basal insulin prescriptions are from the safety population, and represent insulin prescribed during the studies, not only at baseline. Data are
presented as mean ± SD unless otherwise stated. Abbreviations. DPP-4, dipeptidyl peptidase-4; FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide-1
receptor agonist; HbA1c, glycated hemoglobin; n/a, not applicable; SD, standard deviation; SGLT2, sodium-glucose co-transporter 2; SoC, standard of care.
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HbA1c in both groups, with values decreasing to 7.65 (1.19) %
(60.1 [13.0] mmol/mol) with Gla-300 and 7.54 (1.17) % (58.9
[12.8] mmol/mol) with SoC basal insulins at month 6. HbA1c
remained stable through to month 12, when values were 7.64
(1.09) % (60.0 [11.9] mmol/mol) with Gla-300 and 7.59 (1.16) %
(59.4 [12.7] mmol/mol) with SoC basal insulins. REACH met its
primary outcome, demonstrating non-inferiority of Gla-300 ver-
sus SoC basal insulins in terms of HbA1c change from baseline
to month 6 (LS mean difference between groups 0.12; [95% CI
0.046 to 0.281]% [1.3 (0.5 to 3.1) mmol/mol]) (Figure 1(a)).
There was also no difference between the groups in HbA1c
change from baseline to month 12 (LS mean difference 0.07
[95% CI 0.087 to 0.227]% [0.8 (1.0 to 2.5) mmol/mol])
(Figure 1(a)).
In REGAIN, mean (SD) baseline HbA1c values were 8.58 (1.10)
% (70.3 [12.0] mmol/mol) with Gla-300 and 8.51 (1.18) % (69.5
[12.9] mmol/mol) with SoC basal insulins. There was only a
modest decrease in HbA1c from baseline in both treatment
groups, to 6-month values of 8.32 (1.24) % (67.4 [13.6]
mmol/mol) with Gla-300 and 8.11 (1.18) % (65.1 [12.9] mmol/mol)
with SoC BIs. From month 6 onwards there was further HbA1c
reduction in the Gla-300 group (to 8.17 [1.19] % [65.8 (13.0)
mmol/mol] at month 12), but little change in the SoC basal
insulins group (month 12 value of 8.17 [1.28] % [65.8 (14.0)
mmol/mol]). In REGAIN, the primary 6-month outcome did not
achieve statistical non-inferiority of Gla-300 versus SoC basal
insulins in terms of HbA1c change from baseline (LS mean dif-
ference 0.17 [95% CI 0.015–0.329]% [1.9 (0.2–3.6) mmol/mol]);
however, by 12 months the difference in HbA1c between
treatment groups was observed to be nominally within the
non-inferiority margins (LS mean difference 0.03 [95% CI
0.199 to 0.145]% [0.3 (2.2 to 1.6) mmol/mol]) (Figure 1(b)).
In both studies, the degree of insulin titration reflected by
dose changes was low in the Gla-300 and SoC basal insulin
treatment arms (Figure 1(c,d)). In REACH, mean (SD) daily dose
increased from baseline values of 0.18 (0.07) U/kg for Gla-300
and 0.17 (0.07) U/kg for SoC basal insulin, to month 6 values
of 0.32 (0.18) U/kg for Gla-300 and 0.30 (0.18) U/kg for SoC
basal insulins (mean increases of 0.14 and 0.13U/kg, respect-
ively). In REGAIN, mean (SD) daily dose increased from baseline
values of 0.41 (0.21) U/kg for Gla-300 and 0.41 (0.23) U/kg for
SoC basal insulins, to month 6 values of 0.49 (0.27) U/kg for
Gla-300 and 0.46 (0.26) U/kg for SoC basal insulins (mean
increases of 0.08 and 0.06U/kg, respectively). By month 12, the
daily dose had increased to 0.35 (0.19) U/kg for Gla-300 and
0.33 (0.20) U/kg for SoC basal insulins in REACH (mean
increases of 0.17 and 0.15U/kg, respectively), and to 0.52 (0.28)
U/kg for Gla-300 and 0.48 (0.26) U/kg for SoC basal insulins in
REGAIN (mean increases of 0.11 and 0.07U/kg, respectively).
HbA1c targets
The proportion of patients who achieved the HbA1c target
<7.0% was low and similar in the Gla-300 and SoC basal
insulin arms during the 12-month period in both REACH and
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Figure 1. LS mean (±SE) change from baseline in HbA1c by visit during the 12-month randomized period in (a) REACH and (b) REGAIN and change in insulin dose
in (c) REACH and (d) REGAIN (ITT populations). Abbreviations. BI, basal insulin; CI, confidence interval; HbA1c, glycated hemoglobin; ITT, intent-to-treat; LS, least
squares; M, month; SE, standard error; SoC, standard of care.
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a 1% decrease in HbA1c at month 6 that was maintained at
month 12 was similar in both treatment groups (Gla-300,
44.0% (155/352); SoC basal insulin, 47.9% (168/351)). In
REGAIN, the percentage of patients with a 0.5% decrease
in HbA1c at month 6 that was maintained at month 12 was
similar in both treatment groups (Gla-300, 26.9% (82/305);
SoC basal insulin, 27.3% (83/304)).
FPG changes
In REACH, mean (SD) baseline FPG was 11.62 (3.43) mmol/L
(209.3 [61.9] mg/dL) with Gla-300 and 11.67 (3.80) mmol/L
(210.2 [68.5] mg/dL) with SoC basal insulins. FPG decreased
similarly in both groups to month 6 values of 8.70 (2.49)
mmol/L (156.7 [44.9] mg/dL) with Gla-300 and 8.42 (2.55)
mmol/L (151.7 [45.9] mg/dL) with SoC basal insulins, and to
month 12 values of 8.25 (2.40) mmol/L (148.7 [43.2] mg/dL)
with Gla-300 and 8.35 (2.62) mmol/L (150.5 [47.2] mg/dL) with
SoC basal insulins.
In REGAIN, mean baseline FPG was 9.85 (3.16) mmol/L (177.5
[57.0] mg/dL) with Gla-300 and 10.03 (3.12) mmol/L (180.7
[56.2] mg/dL) with SoC basal insulins, decreasing to 9.21 (2.75)
mmol/L (165.9 [49.5] mg/dL) and 8.74 (2.91) mmol/L
(157.5 [52.5] mg/dL) at month 6, and to 8.62 (3.04) mmol/L
(155.4 [54.9] mg/dL) and 8.67 (3.14) mmol/L (156.2 [56.7]
mg/dL) at month 12, respectively.
In both REACH and REGAIN, LS mean FPG change from
baseline to month 12 was similar across treatment arms
(REACH, 3.32mmol/L [59.9mg/dL] with Gla-300 and
3.27mmol/L [58.8mg/dL] with SoC basal insulins; REGAIN,
1.30mmol/L [23.5mg/dL] with Gla-300 and 1.26mmol/L
[22.8mg/dL] with SoC basal insulins). In both studies, the
month 12 FPG values in either treatment arm were above
the ADA FPG target range specified in the protocol.
Hypoglycemia
Incidence and rates of anytime (24 h) hypoglycemia were low
and similar in the Gla-300 and SoC basal insulin arms in
REACH and REGAIN (Table 3). Benefits were observed for
Gla-300 versus SoC basal insulins in REGAIN, for nocturnal
(00.00am–05.59am) symptomatic documented (3.9mmol/L)
hypoglycemia (OR 0.48 [95% CI 0.26–0.87]; RR 0.45
[0.20–0.97]) and severe and/or symptomatic documented
(3.9mmol/L) hypoglycemia (OR 0.47 [0.27–0.84]; RR 0.42
[0.20–0.87])(Table 4).
Bodyweight changes
In both REACH and REGAIN, the LS mean change in patients’
body weight from baseline to month 12 was modest and
similar in both treatment groups (Figure 2).
Incidence of adverse events
In both REACH and REGAIN, the AE profile was similar
between treatment arms. In REACH, 208 (59.4%) and 194
(55.4%) patients in the Gla-300 and SoC basal insulin arms,
respectively, had a treatment-emergent AE (TEAE), of whom 14
(4.0%) in each treatment arm had a TEAE considered as related
to study drug. Two (0.6%) patients in each treatment arm had
a TEAE leading to death. Two (0.6%) (Gla-300) and 3 (0.9%)
patients (SoC basal insulins) discontinued treatment due to
TEAEs. In REGAIN, 184 (60.5%) and 170 (55.9%) patients in the
Gla-300 and SoC basal insulin arms, respectively, had a TEAE,
of whom 6 (2.0%) (Gla-300) and 2 (0.7%) (SoC basal insulins)
had a TEAE considered as related to study drug. Two (0.7%)
patients in each treatment arm had a TEAE leading to death.
Table 2. Proportion of patients at HbA1c target during the 12-month randomized period by visit (ITT population).
REACH REGAIN
Patients at HbA1c target, n (%) Gla-300 (n¼ 352) SoC basal insulin (n¼ 351) Gla-300 (n¼ 305) SoC basal insulin (n¼ 304)
Baseline
<6.5% 0 (0) 0 (0) 0 (0) 0 (0)
<7.0% 4 (1.1) 2 (0.6) 1 (0.3) 2 (0.7)
<7.5% 40 (11.4) 35 (10.0) 36 (11.8) 54 (17.8)
<8.0% 89 (25.3) 83 (23.6) 105 (34.4) 119 (39.1)
Imputed as failure 0 (0) 0 (0) 0 (0) 0 (0)
Month 3
<6.5% 34 (9.7) 35 (10.0) 3 (1.0) 7 (2.3)
<7.0% 80 (22.7) 113 (32.2) 19 (6.2) 36 (11.8)
<7.5% 159 (45.2) 174 (49.6) 65 (21.3) 81 (26.6)
<8.0% 228 (64.8) 232 (66.1) 128 (42.0) 147 (48.4)
Imputed as failure 12 (3.4) 8 (2.3) 8 (2.6) 7 (2.3)
Month 6
<6.5% 42 (11.9) 53 (15.1) 11 (3.6) 7 (2.3)
<7.0% 102 (29.0) 107 (30.5) 26 (8.5) 44 (14.5)
<7.5% 175 (49.7) 189 (53.8) 71 (23.3) 92 (30.3)
<8.0% 231 (65.6) 247 (70.4) 119 (39.0) 157 (51.6)
Imputed as failure 10 (2.8) 11 (3.1) 14 (4.6) 8 (2.6)
Month 12
<6.5% 31 (8.8) 38 (10.8) 9 (3.0) 12 (3.9)
<7.0% 85 (24.1) 102 (29.1) 34 (11.1) 31 (10.2)
<7.5% 166 (47.2) 176 (50.1) 87 (28.5) 93 (30.6)
<8.0% 231 (65.6) 228 (65.0) 137 (44.9) 151 (49.7)
Imputed as failure 22 (6.3) 18 (5.1) 24 (7.9) 17 (5.6)
Abbreviations. HbA1c, glycated hemoglobin; ITT, intent-to-treat; SoC, standard of care
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Eight (2.6%) (Gla-300) and 2 (0.7%) patients (SoC basal insulins)
discontinued treatment due to TEAEs.
Patient support program (PSP)
In REACH, 44.3% (155/350) of patients in the Gla-300 group
at least partially participated in the core PSP, and 8.6%
(30/350) of patients in the SoC basal insulin group at least
partially participated in any PSP. In REGAIN, 51.0% (155/304)
of patients in the Gla-300 group and 2.6% (8/304) of patients
in the SoC basal insulin group participated in a PSP.
Discussion
REACH and REGAIN are the first randomized pragmatic stud-
ies in T2DM to allow for direct treatment comparisons of
patient outcomes in a real-life setting, and are part of a
larger real-world evidence program (including another prag-
matic study, ACHIEVE-CONTROL26, in 3300 insulin-naïve
T2DM patients in North America). In both studies, the pri-
mary outcome was non-inferiority of Gla-300 versus
SoC basal insulin in terms of HbA1c change from baseline to
month 6. The primary outcome was met in REACH but not in
REGAIN, although only a modest HbA1c reduction was seen
in both treatment arms over the full study period in REGAIN,
and no difference in HbA1c change between the groups was
shown after 12 months in either study. It may be notable
that overall basal insulin dose increases were minimal in
both studies, particularly in REGAIN.
The failure to achieve non-inferiority for the difference in
HbA1c change in REGAIN compared to SoC was unexpected.
It is possible that this simply reflects no benefit, or even a
lack of parity, with Gla-300 versus other SoC BIs in a real-
Table 3. Hypoglycemia events occurring at any time of day (24 h) during the 12-month on-treatment period in REACH and REGAIN (safety population).
REACH REGAIN












Participants experiencing  1
hypoglycemic event, n (%)
OR (95% CI) OR (95% CI)
Any hypoglycemia 117 (33.4) 110 (31.4) 1.10 (0.80–1.52) 113 (37.2) 113 (37.2) 1.00 (0.72–1.39)




73 (20.9) 65 (18.6) 1.16 (0.80–1.70) 80 (26.3) 76 (25.0) 1.07 (0.74–1.54)
Documented < 3.0mmol/L
(<54mg/dL)





79 (22.6) 67 (19.1) 1.24 (0.86–1.80) 83 (27.3) 81 (26.6) 1.03 (0.72–1.48)
Documented < 3.0mmol/L
(<54mg/dL)
26 (7.4) 24 (6.9) 1.09 (0.61–1.94) 38 (12.5) 36 (11.8) 1.07 (0.65–1.74)
Number of events (events per
patient-year)
RR (95% CI) RR (95% CI)
Total patient years 337.21 335.52 295.05 294.14
Any hypoglycemia 573 (1.70) 664 (1.98) 0.87 (0.56–1.33) 688 (2.33) 675 (2.29) 1.02 (0.68–1.53)




310 (0.92) 315 (0.94) 0.98 (0.55–1.76) 258 (0.87) 366 (1.24) 0.70 (0.44–1.11)
Documented < 3.0mmol/L
(<54mg/dL)





325 (0.96) 326 (0.97) 1.00 (0.57–1.75) 267 (0.90) 393 (1.34) 0.67 (0.43–1.05)
Documented < 3.0mmol/L
(<54mg/dL)
56 (0.17) 53 (0.16) 1.05 (0.51–2.18) 72 (0.24) 97 (0.33) 0.74 (0.42–1.30)
Abbreviations. CI, confidence interval; OR, odds ratio; RR, rate ratio; SoC, standard of care. The 12-month on-treatment period was defined as the time from the
first study drug intake until one day after last injection of the study drug. ORs and their corresponding 95% CIs are based on a logistic regression with treat-
ment arm as a fixed effect and adjusting for randomization strata: HbA1c (<9%/>9%), sulfonylurea use (yes/no) and GLP-1 RA use (yes/no). Estimated RRs and
their corresponding 95% CIs are based on an over-dispersed Poisson regression model with a log-link function and with treatment arm as a fixed effect, adjust-
ing for randomization strata: HbA1c (<9%/9%), SU use (yes/no) and GLP-1RA use (yes/no).
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world scenario. However, given the results from previous
RCTs6,7, we feel that this is unlikely. The EDITION program of
RCTs, with a treat-to-target approach, consistently demon-
strated non-inferiority of Gla-300 versus Gla-100 (the most
commonly used SoC basal insulin in both REACH and
REGAIN) in terms of HbA1c reduction, regardless of previous
insulin exposure27. Compared with these RCTs, REACH and
REGAIN involved nearly no restriction to participation, did
not include predefined titration regimens or mandated over-
sight of titration during the studies, and involved less fre-
quent contact between the patients and HCPs to ensure
close titration support, so direct comparisons with REACH
and REGAIN are difficult. Moreover, in REACH and REGAIN,
average baseline HbA1c (8.99 and 8.58%, respectively, in the
Gla-300 arms) and FPG (11.62 and 9.85mmol/L, respectively,
in the Gla-300 arms) was higher than seen in the EDITION
program (HbA1c, 8.49% in EDITION 3 [insulin-naïve partici-
pants] and 8.28% in EDITION 2 [basal insulin plus OADs];
FPG, 9.93mmol/L in EDITION 3 and 8.24mmol/L in EDITION
2)6,28. The high baseline HbA1c levels are an indication of the
difficulties associated with glycemic management in real-life
clinical practice.
Limited insulin titration was observed in REACH and REGAIN
(despite an apparent difference in dose increase between
treatment arms in REGAIN) compared with the EDITION RCTs
that employed a treat-to-target approach; Gla-300 dose
increase over 12 months was 0.17U/kg in REACH versus
0.48U/kg in EDITION 328 and 0.11U/kg in REGAIN versus
0.33U/kg in EDITION 26. Crucially, dose titration in REACH and
REGAIN was performed at the discretion of the investigators,
without a predefined titration algorithm or a titration commit-
tee. In comparison, patients in the EDITION program were
titrated to a fasting SMPG target of 4.4–5.6mmol/L
(80–100mg/dL; below the ADA target range), which translated
to greater increases in insulin dose and greater proportions of
patients achieving glycemic targets, than was observed in
REACH or REGAIN. The minimal basal insulin dose increase in
REACH and REGAIN limited the ability to compare other out-
comes across treatment arms and may also have driven the
low incidence of hypoglycemia compared with the EDITION
program27 and the BRIGHT study (Gla-300 versus insu-
lin degludec)10.
Basal insulin titration in REGAIN was even more limited
than in REACH, in both treatment arms, and this overall
therapeutic inertia may be related to the failure to achieve
non-inferiority for the primary outcome at month 6. The
EDITION studies demonstrated that 12% more Gla-300 than
Gla-100 was required for equivalent glycemic control owing
Table 4. Nocturnal (00.00am–05.59am) hypoglycemia events occurring during the 12-month on-treatment period in REACH and REGAIN (safety population).
REACH REGAIN












Participants experiencing  1
hypoglycemic event, n (%)
OR (95% CI) OR (95% CI)
Any hypoglycemia 35 (10.0) 25 (7.1) 1.45 (0.85–2.48) 34 (11.2) 48 (15.8) 0.67 (0.42–1.08)




20 (5.7) 15 (4.3) 1.36 (0.68–2.72) 18 (5.9) 35 (11.5) 0.48 (0.26–0.87)
Documented < 3.0mmol/L
(<54mg/dL)





21 (6.0) 18 (5.1) 1.18 (0.62–2.26) 20 (6.6) 39 (12.8) 0.47 (0.27–0.84)
Documented < 3.0mmol/L
(<54mg/dL)
9 (2.6) 10 (2.9) 0.90 (0.36–2.24) 11 (3.6) 15 (4.9) 0.72 (0.33–1.61)
Number of events (events per
patient-year)
RR (95% CI) RR (95% CI)
Total patient-years 337.21 335.52 295.05 294.14
Any hypoglycemia 83 (0.25) 51 (0.15) 1.63 (0.87–3.05) 100 (0.34) 132 (0.45) 0.75 (0.42–1.36)




43 (0.13) 29 (0.09) 1.48 (0.68–3.21) 39 (0.13) 87 (0.30) 0.45 (0.20–0.97)
Documented < 3.0mmol/L
(<54mg/dL)





44 (0.13) 34 (0.10) 1.29 (0.62–2.70) 41 (0.14) 98 (0.33) 0.42 (0.20–0.87)
Documented < 3.0mmol/L
(<54mg/dL)
11 (0.03) 12 (0.04) 0.92 (0.36–2.32) 13 (0.04) 29 (0.10) 0.45 (0.18–1.12)
CI: confidence interval; OR: odds ratio; RR: rate ratio; SoC: standard of care. The 12-month on-treatment period was defined as the time from the first study
drug intake until one day after last injection of the study drug. ORs and their corresponding 95% CIs are based on a logistic regression with treatment arm as a
fixed effect and adjusting for randomization strata: HbA1c (<9%/>9%), sulfonylurea use (yes/no) and GLP-1RA use (yes/no). Estimated RRs and their correspond-
ing 95% CIs are based on an over-dispersed Poisson regression model with a log-link function and with treatment arm as a fixed effect, adjusting for random-
ization strata: HbA1c (<9%/9%), SU use (yes/no) and GLP-1 RA use (yes/no).
Bold values represent p < 1.
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to differences in bioavailability27, so a lack of titration could
have a greater impact on the outcomes of Gla-300. However,
it has not been determined if the dose requirements seen in
the EDITION RCTs are reflected in clinical practice. In addition
to titration inertia, the lack of therapy intensification with
short-acting insulins is notable in REGAIN, even though
investigators were allowed to intensify therapy with oral anti-
hyperglycemic agents and/or injectable therapy as they do
in their clinical practice.
There are many reasons why patients may not have up-
titrated their basal insulin dose to achieve glycemic control,
including perceived barriers such as hypoglycemia and
weight gain13,14,16–18. However, it is likely that the lack of
standardized titration-to-target algorithms for basal insulins
is key to the suboptimal basal insulin titration seen in both
REACH and REGAIN and may highlight the need for tools to
facilitate such titration. The recent ADA/EASD consensus
report recognizes the necessity of titrating basal insulins to a
fasting blood glucose target using an evidence-based algo-
rithm2. Empowering patients to increase their own basal
insulin dose is also important2, and self-titration has been
shown to be superior to physician-led titration in the recent
TAKE CONTROL study29. In TAKE CONTROL, which included
both insulin-naïve and insulin pre-treated participants with
T2DM, 72% of participants achieved the ADA-defined PG tar-
get of 4.4–7.2mmol/L (80–130mg/dL) in the self-titra-
tion group.
Substantially more people in the Gla-300 group than in
the SoC basal insulin group, in both REACH and REGAIN, uti-
lized a PSP. The minimal basal insulin dose increases and
HbA1c reduction with Gla-300, despite the availability of a
PSP, maybe a further indication of substantial titration inertia.
However, although the Gla-300 PSP (COACH) has been
shown to improve persistence and adherence to basal insulin
therapy20,21, it does not include any titration-to-target guid-
ance. There is no evidence that the COACH PSP would influ-
ence the outcomes of REACH and REGAIN, and so it should
not necessarily be expected to improve insulin dose titration.
The impact of PSPs on outcomes in REACH and REGAIN was
not a predefined objective of either study and could not be
analyzed because the use of a program was determined after
randomization (patients could decide to use a PSP at any
point throughout the study), so this remains a poten-
tial confounder.
In addition to real-life therapeutic inertia, the results pre-
sented here may be partly influenced by the study design,
keeping in mind that REACH and REGAIN were the first
randomized pragmatic studies in the field of basal insulin
treatment and so novel in this field. Power calculations for
REACH and REGAIN were based on data from regulatory
RCTs and therefore assumed a slight benefit in favor of
Gla-300, which may have unduly constrained patient num-
bers. HbA1c targets may require tailoring to the individual
patient and given the less-stringent inclusion criteria for
REACH and REGAIN compared with regulatory RCTs, the pre-
defined targets (<7%) may have been too ambitious for
some patients. Such a shift towards patient-centered care is
advocated in the recent ADA and EASD consensus report on
hyperglycemia management2, and future real-world studies
of basal insulins should consider individualized targets. It is
notable that both REACH and REGAIN were initiated close to
the launch of Gla-300, therefore real-world experience of its
use was lacking during the studies. Investigators may have
exercised caution in using new basal insulin but would likely
have had long-term experience with the basal insulin used in
the SoC group. A potentially cautious approach to Gla-300
use could have been reinforced by the lack of an enforced
titration algorithm. In addition, investigators may have been
more familiar with participating in regulatory RCTs, in which
visit frequency is higher and monitoring of study protocol
execution and oversight of dose titration and other proce-
dures is much stricter than in pragmatic studies. The wide
range of concomitant antihyperglycemic therapies used by
the heterogeneous populations included in REACH and
REGAIN, that may not reflect regulatory RCTs (for example, a
relatively high proportion of people using DPP-4 inhibitors in
both studies), change in dose of these non-insulin anti-
hyperglycemic therapies during the studies and the previous
basal insulin use in REGAIN (in particular whether a once- or
twice-daily regimen was used), may also have impacted
on outcomes.
In contrast with the results presented here, other RWE
studies employing retrospective analysis of electronic health
records have demonstrated benefits of Gla-300 versus first-
generation basal insulins in clinical practice, with comparable
glycemic improvement and lower hypoglycemia risk in pro-
pensity score-matched cohorts11,12. In these RWE studies, the

















































Figure 2. LS mean (±SE) change in body weight from baseline to month 12
during the 12-month on-treatment period in REACH (a) and REGAIN (b) (safety
populations). The 12-month on-treatment period was defined as the time from
the first study drug intake until one day after last injection of the study drug.
Abbreviations. BI, basal insulin; LS, least squares; M, month; SE, standard error;
SoC, standard of care.
CURRENT MEDICAL RESEARCH AND OPINION 579
characteristics, and there was no intervention that may have
led to a “study effect”; however, there was no randomization
to control for unknown confounders and no way to deter-
mine if more basal insulin titration occurred compared with
REACH and REGAIN.
Conclusions
Therapeutic inertia is a global unmet medical need, one that
the ADA and EASD are seeking to address in their recent
consensus report. In both REACH and REGAIN, no differences
in glycemic control or hypoglycemia outcomes were seen
between treatment arms over 12 months. However, the sub-
optimal basal insulin titration seen in both trials reflects con-
siderable therapeutic inertia, limiting the ability to compare
outcomes between the newer basal insulin (Gla-300) and
SoC basal insulin arms. Results from REACH and REGAIN
show that, in addition to appropriate insulin therapy, more
dedicated basal insulin titration support using evidence-
based algorithms may be required for patients and health-
care providers in order to help patients with uncontrolled
T2DM to achieve glycemic targets. These studies also high-
light the importance of appropriate patient selection and
treatment. Appropriate titration of Gla-300 and other second-
generation basal insulin analogues may be required to real-
ize their potential clinical benefits of decreasing the risk of
hypoglycemia versus older basal insulins.
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